NSC-125973 |
BMS-181339-01 |
TAXOL 100 |
ABRAXANE |
DHP 107 |
NK 105 |
ABI-007 |
TAXOL |
BMS 181339-01 |
QW-8184 |
MBT 0206 |
PACITAXEL |
PAXENE |
PACLITAXEL |
INTAXEL |
CAPXOL |
MITOTAX |
CYCLOPAX |
GENEXOL |
LIPOPAC |
ANZATAX |
ONXOL |
TAXALBIN |
GENETAXYL |
TAXOL A |
PLAXICEL |
YEWTAXAN |
5BETA,20-EPOXY-1,2-ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXYTAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE |
EBETAXEL |
chembl:CHEMBL428647 |
drugbank:01229 |
rxcui:56946 |
chemidplus:33069-62-4 |
pubchem.compound:36314 |
Year of Approval | 1992 |
Drug Class | antineoplastic agents |
Drug Indications | for treatment of peripheral arterial disease (PAD) |
Drug Indications | antiinflammatory agent,DMARD |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
n/a |
inhibitor (inhibitory) |
Trial Name | oral paclitaxel |
Novel drug target | Established target |
Trial Name | Abraxane |
n/a |
inhibitor (inhibitory) |
Mechanism of Interaction | Tubulin inhibitor |
Direct Interaction | yes |
n/a |
n/a |
combination therapy | Sapitinib + Paclitaxel |
Indication/Tumor Type | inflammatory breast carcinoma |
Response Type | sensitive |
n/a |
combination therapy | Carboplatin + Paclitaxel + Veliparib |
Indication/Tumor Type | breast cancer |
Response Type | predicted – sensitive |
n/a |
combination therapy | Ipatasertib + Paclitaxel |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | predicted – sensitive |
n/a |
Trial Name | liposomal encapsulated paclitaxel (LEP) |
Novel drug target | Established target |
PACLITAXEL | Primary Drug Name |
Drug Class | antineoplastic agents |
Year of Approval | 1992 |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
C1411 | NCI drug code |
CHEMBL428647 | ChEMBL Drug ID |
C1411 | NCI drug code |
D0C4RB | TTD Drug ID |